Q-omics provides the consensus-scored LZTS2 profile across patient tissues and cancer cell-line models. LZTS2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LZTS2 is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, LZTS2 RNA expression shows 18,779 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KIRP, and THYM as cancer lineages where LZTS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LZTS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LZTS2 survival associations across molecular data types. LZTS2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LZTS2 RNA expression–survival associations across cancer types. High LZTS2 expression shows unfavorable associations in KIRC, LIHC, ACC, LAML, READ and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LZTS2 RNA expression.
This table summarizes LZTS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LZTS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LZTS2 shows higher tumor expression in KIRP, THCA, LIHC, HNSC, KIRC and CHOL. The KIRP box plot shows higher LZTS2 RNA expression in tumor versus normal tissue (log2 FC = +0.932, t-test p < 0.001).
This table shows molecular features associated with LZTS2 in patient tissues and cancer cell lines. In patient samples, LZTS2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LZTS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
